ERBB2 and Hand-foot syndrome: In a clinical trial in patients with residual HER2-negative invasive breast cancer evaluating adjuvant capecitabine following preoperative chemotherapy, the incidence of HFS in the capecitabine arm was as high as 73.4% [90].